At the news
? BULLISHIMPACT 8/10 DEFA14A filed Jun 12, 2026 at 17:24 ET
XOMA Royalty Corp filed additional definitive proxy soliciting materials (DEFA14A) confirming its acquisition by Ligand Pharmaceuticals is expected to close on or about July 14, 2026. The company also announced full redemption of all outstanding Series A and Series B perpetual preferred stock at $25.00 per share plus accrued dividends, effective July 14, 2026, and set a CVR record date of July 13, 2026, for common shareholders. The merger timeline is crystallizing, with the shareholder vote approaching.
- Merger with Ligand Pharmaceuticals expected to close on or about July 14, 2026
- Full redemption of 984,000 shares of Series A Preferred Stock at $25.00 per share plus accrued dividends
- Full redemption of 1,760.5 shares of Series B Preferred Stock (1,760,500 depositary shares) at $25.00 per depositary share plus accrued dividends
- Preferred stock redemption effective July 14, 2026, and shares will cease listing on Nasdaq
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access